Compass Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing antibody-based therapies for cancer and autoimmune disease, working on programs such as bispecific antibodies and antibody-drug conjugates. It grew out of Boston's biotech ecosystem, founded by drug-development scientists in the early 2010s to build a pipeline of novel antibody medicines aimed at solid tumors. The company takes its name from the guiding idea of using antibodies to "point" the immune system, like a compass, toward cancer cells — a naming quirk that frames its whole mission.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 13G/APassive | 4% | 7.21M | Aug 14, 2026 |
| Vivo Opportunity, LLC | 13G/APassive | 4% | 7.21M | Aug 14, 2026 |
| Vivo Opportunity Cayman Fund, L.P. | 13G/APassive | 0.3% | 549.5K | Aug 14, 2026 |
| Vivo Opportunity Cayman, LLC | 13G/APassive | 0.3% | 549.5K | Aug 14, 2026 |
| STATE STREET CORPORATION | 13GPassive | 5.5% | 9.95M | Aug 7, 2026 |
| BVF PARTNERS L P/IL | 13G/APassive | 4.3% | 7.76M | May 15, 2026 |
| BVF INC/IL | 13G/APassive | 4.3% | 7.76M | May 15, 2026 |
| LAMPERT MARK N | 13G/APassive | 4.3% | 7.76M | May 15, 2026 |
| BVF GP HOLDINGS LLC | 13G/APassive | 4% | 7.17M | May 15, 2026 |
| BIOTECHNOLOGY VALUE FUND L P | 13G/APassive | 2.3% | 4.14M | May 15, 2026 |